StockNews.AI
SNN
StockNews.AI
106 days

Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland

1. Smith+Nephew promotes CORI Surgical System in a European roadshow. 2. The system improves surgery precision and efficiency for joint replacements. 3. Workshops offer hands-on experience for surgeons and clinic staff. 4. Compatibility with various knee and hip implants expands market potential.

8m saved
Insight
Article

FAQ

Why Bullish?

The CORI Surgical System's advancements can lead to increased adoption, driving sales and market share.

How important is it?

The article emphasizes new product capabilities that can significantly affect surgical market dynamics and SNN's financials.

Why Long Term?

Market expansion and long-term contracts are expected as robotic surgery becomes more favorable among clinics.

Related Companies

SNNSYKZBHABT
“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzerland until returning to Berlin on 28 October for DKOU 2025 – the largest Orthopaedics congress in Europe. The goal of the tour is to demonstrate the capabilities of the CORI Surgical System to surgeons, operating room (OR) technical staff, and administrators at surgical clinics that perform hip and knee replacement procedures but have not yet made the jump to using robotics. Visits will include a private CORI workshop at the clinic for those who register. The CORI Surgical System features image-agnostic smart mapping to register 3D models of the joint in surgery, intra-operative gap balancing, and real-time planning for a truly personalized surgical experience. Additionally, the system is: Smart: Image-agnostic registration and real-time gap assessment are designed to help optimize alignment and balancing. Efficient: Ergonomic handpiece with burr designs deliver twice the cutting volume resulting in 29% faster resection.** Enhanced workflow requires fewer steps and may help save time in the OR.*** Compact: The uniquely small footprint and compact design make it easily transportable and able to fit in today’s crowded operating room settings. CORI Roadshow The capabilities of the CORI Surgical System continue to expand and now include total, partial and revision knee systems, including cemented and cementless primary knee implant technology. It is also compatible with implants and approaches for total hip arthroplasty. The CORI Virtual Planner provides an interactive, fully functional software tool for surgeons to become familiar with creating a surgical plan on the CORI Surgical System. To learn more about the CORI Surgical System, please visit the CORI on Tour webpage CORI Roadshow.  - ends – Media Enquiries  Dave Snyder          +1 (978) 749-1440  Smith+Nephew      david.snyder@smith-nephew.com References *Manufacturer: Blue Belt Technologies, Inc., 2875 Railroad Street, Pittsburgh, PA 15222 USA ** Compared to conventional techniques. *** Compared to the NAVIO◊ OR system and earlier software versions. 29 % faster resection proven in TKA studies on cadaver donor  About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements  This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Related News